APPLIED PHARMACEUTICAL TOXICOLOGY 2021 - Virtual Event
Save the Date for 2021!
May 10 - 11, 2021 Discovery Toxicology Workshop
May 18-19, 2021 Development Toxicology Workshop
Plenary Speakers for 2021
![]() |
Laura Dill Morton, DVM, PhD Director of Toxicology at Aclairo Pharmaceutical Development Group, Inc. Engaging CBER on Preclinical Gene Therapy Projects - a Consultant's Perspective |
|
Daniel Nomura, PhD Professor of Chemical Biology, University of California at Berkeley Reimagining Druggability using Chemoproteomic Platforms |
||
![]() |
Lisa Plitnick, PhD Distinguished Scientist, Merck Discovery and Development of Vaccines and Worldwide Regulatory Experience |
![]() |
Jacinta Shenton, PhD Senior Scientific Director, Nonclinical Safety Therapeutic Area Lead Immuno-Oncology, Janssen TBA |
Speakers Confirmed for 2021
![]() |
Ahmet Hoke, MD, PhD Professor of Neurology and Neuroscience, Director of Neuromuscular Division, Johns Hopkins School of Medicine Title TBA |
![]() |
Christopher Aluise, PhD Senior Research Scientist, Toxicology, Eli Lilly and Company Title TBA |
|
|
||||
![]() |
Lauren E. Black, PhD Distinguished Scientist, Scientific Advisory Services, Charles River Laboratories Adapting Traditional Tox Strategy to Patients with High Risk, Genetic Disorders: Do Regulations Speak to the Heart of the Issue? |
![]() |
Christopher Brynczka, PhD, DABT Senior Principal Scientist, Merck STINg in IO Space Immunomodulators |
|
|
||||
![]() |
Juliane Gust, MD, PhD Center for Integrative Brain Research, Seattle Children's Hospital CAR T Neurotoxicity: Translational Insights |
|
Tomomi Kiyota, PhD Senior Scientist, Investigative Toxicology, Genentech Antibiotic-Induced Renal Toxicity Evaluation Using a Proximal Tubule On-a-Chip |
|
|
||||
![]() |
Hervé Lebrec, PharmD, PhD, DABT Scientific Director, Translational Safety & Bioanalytical Services, Amgen Experience with Nonhuman Primate Models in CAR-T Therapy Nonclinical Safety Assessment |
|
Kerry Jo Lee, MD Acting Associate Director for Rare Diseases, OND/CDER/FDA Regulatory Challenges and Considerations in Rare Disease Drug Development |
|
|
||||
![]() |
Changhua Ji, MD, PhD Associate Research Fellow, Pfizer Nonclinical Evaluation of CD3 Bispecific Antibodies |
|
Matt Liu, PhD, DABT Fellow, Toxicology, Regeneron Pharmaceuticals, Inc. Rapid Development of REGN-COV2, an Anti-Spike Antibody Cocktail for Treatment and Prevention of COVID-19 |
|
|
||||
![]() |
Lisa Mangus, DVM, PhD, DACVP Assistant Professor, Dept. of Molecular & Comparative Pathobiology, Johns Hopkins School of Medicine Intra-Epidermal Nerve Fiber Analysis: a Sensitive, Clinically-Relevant Tool for Assessing Sensory Nerve Damage in Animal Models |
|
Kim Maratea, DVM, PhD, DACVP Associate Director Pathology, Oncology Safety, AstraZeneca Early Assessment of Bone Marrow Toxicity in Immunodeficient Mice |
|
|
||||
![]() |
John McNulty, PhD Senior Director/Drug Safety Therapeutic Lead - Rare Disease, Takeda Nonclinical Safety Considerations in the Development of Treatments for Rare Diseases at Shire |
|
Scott Mittelstadt, PhD Director of Investigative Toxicology and Safety Pharmacology, AbbVie CiPA: Practical Applications in Discovery |
|
|
||||
![]() |
Suman Mukherjee, PhD Director, In Vivo PK and TK Group, Safety Assessment, Merck TBA |
|
Lutz Mueller, PhD Distinguished Scientist - Project Leader, F. Hoffmann- La Roche Ltd. Evrysdi - Spinal Muscular Atrophy |
|
|
||||
![]() |
Michael Polydefkis, MD MHS Professor, Neurology, Johns Hopkins University School of Medicine TBA |
|
Chandra Saravanan, PhD Senior Veterinary Pathologist, Novartis Institutes for BioMedical Research Title TBA |
|
|
||||
![]() |
Nicola Stagg, PhD, DABT Senior Scientist/Toxicologist, Genentech Title TBA |
|
Jonathan Stauber, PhD Director, ImaBiotech Role of Drug Exposure Quantification for Safety and Efficacy Evaluation in Non Clinical and Clinical Trials |
|
|
||||
![]() |
Richard Stebbings, PhD Director Oncology ICA Safety Sciences & Discovery, AstraZeneca COVID19 Vaccine AstraZeneca: Mission Impossible EUA |
|
Jessica Sutherland, PhD, DABT Senior Director, Toxicology, Alnylam Pharmaceuticals The Nonclinical Safety Profile of ONPATTRO® (patisiran), a First-in Class RNAi Therapeutic for the Treatment of Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) |
|
|
||||
![]() |
John Vahle, PhD, DABT Senior Research Fellow, Eli Lilly Title TBA |
|
Andy Vo, PhD Senior Scientist - Computational Toxicology, AbbVie Integrating a Big Toxicity Data Framework to Better Evaluate Drug Safety |
|
|
||||
![]() |
Matt Wagoner, PhD Director of Investigative Toxicology, Takeda Pharmaceuticals Title TBA |
|
Larry Whiteley, DVM Senior Director, Pfizer Gene Therapy Non-clinical to Clinical Translation |
|
![]() |
Javier Waksman, MD, DABT, FAACT Vice President, Head of Drug Safety, Sangamo Therapeutics, Inc. Hepatotoxicity Associated with AAV-based Gene Therapy: Evaluation, Mechanism, and Treatment |
![]() |
Ahmet Hoke,
Professor at Johns Hopkins School of Medicine Title TBA |
|
Sessions for the 2021 Discovery Toxicology Workshop
Session I: IO in Discovery Toxicology Space
Session II: Microphysiological Systems (MPS)
Session III: Novel Approaches to Identify Off-target Drivers of Toxicity
Session IV: Case Studies in Investigative Toxicology
Sessions for the 2021 Development Toxicology Workshop
Session I: Vaccine Development and mAb; Regulatory Perspective
Session II: Developing Products for Rare Diseases and Conditions
Session III: Gene Therapy
Session IV: Peripheral Neuropathy
Download APT 2019 Program Guide